Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.41 Insider Own18.89% Shs Outstand9.23M Perf Week-11.09%
Market Cap40.70M Forward P/E- EPS next Y-1.94 Insider Trans1.03% Shs Float7.48M Perf Month-26.50%
Income-27.21M PEG- EPS next Q-0.62 Inst Own38.58% Short Float0.52% Perf Quarter-49.31%
Sales4.09M P/S9.95 EPS this Y1.98% Inst Trans39.43% Short Ratio2.77 Perf Half Y-38.75%
Book/sh2.92 P/B1.51 EPS next Y53.97% ROA-67.32% Short Interest0.04M Perf Year-32.61%
Cash/sh0.26 P/C16.75 EPS next 5Y- ROE-118.62% 52W Range3.66 - 14.50 Perf YTD-35.85%
Dividend Est.- P/FCF- EPS past 5Y- ROI-145.45% 52W High-69.59% Beta0.79
Dividend TTM- Quick Ratio0.34 Sales past 5Y-30.37% Gross Margin9.05% 52W Low20.59% ATR (14)0.37
Dividend Ex-Date- Current Ratio0.34 EPS Y/Y TTM-1938.80% Oper. Margin-660.87% RSI (14)29.30 Volatility7.35% 5.99%
Employees56 Debt/Eq0.30 Sales Y/Y TTM- Profit Margin-664.53% Recom1.00 Target Price20.00
Option/ShortNo / Yes LT Debt/Eq0.23 EPS Q/Q-492.21% Payout- Rel Volume1.42 Prev Close4.46
Sales Surprise5179.17% EPS Surprise14.29% Sales Q/Q-64.69% EarningsNov 14 BMO Avg Volume14.08K Price4.41
SMA20-17.90% SMA50-26.57% SMA200-41.72% Trades Volume20,009 Change-1.12%
Date Action Analyst Rating Change Price Target Change
Nov-05-21Initiated Chardan Capital Markets Buy $17
Feb-23-24 08:00AM
Feb-08-24 08:00AM
Feb-02-24 07:30AM
Jan-23-24 05:58PM
Jan-02-24 04:30PM
01:29PM Loading…
Nov-29-23 01:29PM
Nov-20-23 07:30AM
Nov-14-23 01:35PM
Nov-09-23 07:30AM
Oct-24-23 07:30AM
Oct-19-23 07:30AM
Oct-05-23 07:30AM
11:31AM Loading…
Oct-03-23 11:31AM
Oct-02-23 07:30AM
Aug-21-23 08:30AM
Jul-12-23 11:04AM
Jun-21-23 08:30AM
May-30-23 08:30AM
May-19-23 08:30AM
May-16-23 08:30AM
May-12-23 08:30AM
May-09-23 08:30AM
May-04-23 08:30AM
May-03-23 05:00PM
Apr-26-23 08:30AM
Apr-18-23 08:30AM
08:30AM Loading…
Apr-13-23 08:30AM
Apr-04-23 08:00AM
Mar-31-23 05:00PM
Jan-19-23 08:00AM
Jan-18-23 08:30AM
Jan-10-23 08:00AM
Jan-09-23 08:00AM
Jan-05-23 08:00AM
Dec-15-22 08:30AM
Dec-11-22 08:20AM
Dec-07-22 05:16PM
Nov-21-22 08:14AM
Nov-17-22 05:32AM
Nov-15-22 08:30AM
Nov-08-22 08:30AM
Nov-03-22 09:00AM
Oct-27-22 08:30AM
Sep-28-22 08:00AM
Sep-23-22 08:30AM
Aug-12-22 06:24AM
Aug-10-22 08:15AM
Aug-09-22 04:30PM
Aug-04-22 08:30AM
Jul-11-22 08:00AM
Jul-05-22 08:00AM
Jun-06-22 08:30AM
May-31-22 08:30AM
May-12-22 04:15PM
May-05-22 08:34AM
Apr-05-22 06:00AM
Mar-29-22 04:30PM
Mar-02-22 06:00AM
Mar-01-22 07:30PM
Feb-25-22 06:00AM
Feb-09-22 08:16AM
Jan-24-22 06:00AM
Jan-19-22 05:38PM
Jan-05-22 07:00AM
Dec-20-21 06:00AM
Dec-16-21 06:00AM
Dec-14-21 08:15PM
Dec-01-21 07:00AM
Nov-30-21 07:52PM
Nov-28-21 08:48PM
Nov-25-21 11:27PM
Nov-22-21 05:41PM
Nov-04-21 03:35PM
Oct-25-21 07:40AM
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Sioux Falls, SD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sullivan Eddie JoeChief Executive OfficerDec 07Buy0.881,7401,5315,232,304Dec 08 08:00 AM
King MichaelCHIEF FINANCIAL OFFICERNov 30Buy0.905,0004,5005,000Nov 30 05:00 PM
Reich Samuel JExecutive ChairmanNov 29Buy0.8911,0009,842219,001Nov 30 08:00 AM